<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>high-grade serous carcinoma &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/high-grade-serous-carcinoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 30 Oct 2025 11:19:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>high-grade serous carcinoma &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Podocalyxin Shields Ovarian Cancer Spheroids from NK Cells</title>
		<link>https://bioengineer.org/podocalyxin-shields-ovarian-cancer-spheroids-from-nk-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 30 Oct 2025 11:19:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[high-grade serous carcinoma]]></category>
		<category><![CDATA[NK cell resistance]]></category>
		<category><![CDATA[Ovarian cancer spheroids]]></category>
		<category><![CDATA[Podocalyxin immune evasion]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/podocalyxin-shields-ovarian-cancer-spheroids-from-nk-cells/</guid>

					<description><![CDATA[In a groundbreaking advancement in ovarian cancer research, scientists have uncovered a critical mechanism by which high grade serous carcinoma (HGSC) — the deadliest and most prevalent form of ovarian cancer — evades immune destruction. The study, published in BMC Cancer, reveals that the cell surface protein podocalyxin (PODXL) plays a pivotal role in shielding [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">288943</post-id>	</item>
		<item>
		<title>Risk-Reducing Salpingectomy: Insights from OBGYNs</title>
		<link>https://bioengineer.org/risk-reducing-salpingectomy-insights-from-obgyns/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 06 Jun 2025 09:16:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ethical considerations in reproductive health]]></category>
		<category><![CDATA[high-grade serous carcinoma]]></category>
		<category><![CDATA[obstetrician-gynecologist perspectives]]></category>
		<category><![CDATA[ovarian cancer prevention]]></category>
		<category><![CDATA[risk-reducing salpingectomy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/risk-reducing-salpingectomy-insights-from-obgyns/</guid>

					<description><![CDATA[In a landmark investigation poised to reshape ovarian cancer prevention strategies, obstetrician-gynecologists (OBGYNs) in British Columbia have weighed in on the rising adoption of risk-reducing salpingectomy (RRS) as a standalone surgical intervention. This procedure, focused on the prophylactic removal of fallopian tubes, has gained attention due to mounting evidence that opportunistic salpingectomy significantly lowers the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">248596</post-id>	</item>
	</channel>
</rss>
